Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +75

Biogen (BIIB) Stock Trades Up, Here Is Why - Yahoo Finance

📈 Biogen shares jumped 3.6% after Wells Fargo upgraded its rating to 'Overweight' and raised the price target from $200 to $250.

💊 The stock rallied following the announcement of an exclusive worldwide rights acquisition for the drug candidate felzartamab from TJ Biopharma.

💰 The deal for remaining global rights in Greater China involved a $100 million upfront payment and up to $750 million in potential milestone payments.

🧬 Felzartamab is currently being evaluated in Phase 3 clinical studies for several immune-mediated diseases, representing growth drivers beyond established franchises.

⚖️ Despite the initial pop, shares cooled down slightly to $183.27, trading up 3.3% from the previous close by the end of the session.

📉 Shares are considered relatively low volatility with only 5 moves greater than 5% over the last year, making today's rise notable.

🏛️ Analysts maintain an average 'Overweight' rating with a mean price target of $215.86 for Biogen stock.

💵 Q1 2026 total revenue reached $2.48 billion, surpassing analyst consensus forecasts of $2.25 billion despite the guidance cut.

🧠 Leqembi sales surged 74% year-over-year to $168 million, serving as the primary driver for revenue improvement in the growth products portfolio.

💼 Biogen's attributable net income non-GAAP rose 19% to slightly over $529 million, beating analyst estimates of $2.95 per share.

⚠️ Management lowered full-year profitability guidance due to anticipated impacts from acquired in-process research and development charges.

🏥 Revenue is expected to decline at a mid-single-digit rate compared to 2025 levels according to company projections.

🤝 The $5.6 billion acquisition of Apellis Pharmaceuticals, expected to close soon, is not included in current financial guidance.

🔄 Biogen continues its strategic transformation from multiple sclerosis treatments toward higher-potential therapies like Alzheimer's and neurodegenerative disorders.

📉 Long-term investors who bought shares 5 years ago would see a portfolio value decrease from $1,000 to approximately $670.81 today.

⚠️ The stock previously faced pressure from tariff fears regarding US drug imports, which recently caused the Nifty Pharma index to decline over 5%.

Bullish Signals
  • Biogen shares jumped 3.6% after receiving an analyst upgrade from Wells Fargo, which raised the price target to $250 from $200 and maintained an 'Overweight' rating.
  • The company acquired exclusive worldwide rights for the drug candidate felzartamab, involving a $100 million upfront payment with up to $750 million in potential future milestone payments.
  • Biogen's first-quarter revenue of $2.48 billion beat analyst estimates of $2.25 billion, marking a 2% increase year-over-year.
  • Attributable net income not under GAAP rose 19% to over $529 million, significantly beating the consensus estimate of $2.95 per share.
  • Sales of Leqembi for early Alzheimer's disease surged 74% to $168 million, serving as a key growth driver for the portfolio.
  • The acquisition of Apellis Pharmaceuticals is expected to close in the near future in a deal valued at $5.6 billion, adding significant revenue potential.
  • Wells Fargo expressed confidence in Biogen's late-stage immunology and kidney pipeline programs as potential growth drivers beyond its established franchises.
  • Shares are trading up 3.1% since the beginning of the year and approach their 52-week high, indicating positive market sentiment.
Risk Factors
  • Biogen lowered its full-year profitability guidance, expecting adjusted net income to land at $14.25 to $15.25 per share, which is a full $1 on either end of the range from the previous forecast of $15.25 to $16.25.
  • The company cites anticipated acquired in-process research and development charges as the reason for reducing its profitability outlook.
  • Biogen expects revenue to decline at a mid-single-digit percentage rate compared to 2025, continuing a contraction trend.
  • Despite beating Q1 earnings estimates with $2.48 billion in revenue, investors still reacted negatively to the guidance cut.
  • The stock has been significantly underperforming long-term growth investors, as shares bought 5 years ago would now only be worth $670.81 per share on a $1,000 investment.
  • Biogen's future projections exclude Apellis Pharmaceuticals, which the company is acquiring in a deal valued at $5.6 billion, suggesting potential integration risks or dilution concerns.
  • Analyst uncertainty remains high, as evidenced by Biogen being omitted from The Motley Fool Stock Advisor's list of their 10 best stocks for investors to buy now.
  • The company faces the risk of US tariffs on branded drugs, with reports suggesting imports could face up to 100% tariffs if price negotiations fail, a concern that previously caused a sector-wide sell-off.
Full Analysis
Shares of biotech company Biogen (NASDAQ: BIIB) rose significantly following a combination of positive developments, including an analyst upgrade from Wells Fargo and a major drug acquisition. Wells Fargo raised its rating on Biogen to 'Overweight' and increased its price target from $200 to $250, expressing confidence in the company's late-stage immunology and kidney pipeline programs beyond its established franchises. In a separate but related move, Biogen acquired exclusive worldwide rights for the drug candidate felzartamab from TJ Biopharma for the Greater China Region. The agreement included a $100 million upfront payment with potential future milestone payments reaching up to $750 million. Felzartamab is currently in Phase 3 clinical studies for several immune-mediated diseases, contributing to Biogen's strategic shift away from multiple sclerosis treatments toward higher-potential therapies. The stock performance also reflected the company's recent strong quarterly earnings report published on Wednesday, which helped drive shares up by 6% by the end of trading. For the first quarter of 2026, Biogen reported total revenue of $2.48 billion, representing a 2% increase year over year and surpassing the consensus forecast of $2.25 billion. Profitability improvements were even more dramatic, with non-GAAP attributable net income rising 19% to slightly over $529 million, or $3.57 per share, exceeding analyst estimates of $2.95 per share. Key growth drivers included Leqembi, sales for which zoomed 74% higher to $168 million as it targets early Alzheimer's disease, and Skyclarys, an FDA-approved medication for Friedreich's ataxia. Despite beating earnings estimates, Biogen issued a guidance cut, now expecting adjusted net income between $14.25 and $15.25 per share for the full year, which is down from the previous forecast of $15.25 to $16.25. This adjustment accounts for anticipated in-process research and development charges related to acquisitions. Revenue guidance also remains projected to decline at a mid-single-digit percentage rate compared to 2025, and these projections do not yet include Apellis Pharmaceuticals, which Biogen is acquiring in a deal valued at $5.6 billion expected to close in the near future. As of the reporting period, shares were trading close to their 52-week high of $201.18, with an average analyst price target of $215.86. The recent market reaction to Biogen's news was notable given the stock's historically low volatility, having experienced only five moves greater than 5% over the last year, making today's increase particularly significant in that context. However, this move is viewed by some as meaningful news that may not fundamentally alter long-term perceptions of the business. On a longer-term investment basis, investors who purchased $1,000 worth of Biogen shares five years ago would currently see their holding value at approximately $670.81 per share. Analysts also note that recent sector-wide volatility, such as concerns over potential US tariffs on patented drugs which previously triggered an 18-day-old sell-off affecting international drugmakers, has influenced investor sentiment, though Biogen's specific operational improvements continue to attract attention.